Furiex Pharmaceuticals‘ application for MuDelta, a novel diarrhea-predominant irritable bowel syndrome treatment currently in Phase II, has been granted Fast Track designation by the FDA. “We are extremely pleased our MuDelta program has been granted Fast Track designation by the FDA,” said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex. “The agency recognizes a significant unmet need for new treatment of diarrhea-predominant irritable bowel syndrome. We belie...